Dividends received in the month of November

ASML
Price
Discussão sobre ASML
Postos
595Dividend November 2025
Nov 19 / ASML — Taking a Win, Not Losing Conviction
Opportunity cost over comfort, especially in the current market environment
I sold my ASML position recently at just above $1,000 per share, locking in a solid 40% profit. But this isn’t a bearish take in any way. In fact, it’s not even a mild concern. ASML is still one of the best companies in the world, an untouchable monopoly, and the definition of a “buy and forget” stock. I didn’t sell because something broke, quite honestly I’d be surprised if this was the last time I own the stock. The only reason I sold is because the rally has run far hotter and faster than I anticipated.
ASML was trading at multi-year, if not historical, valuation lows when I bought. Now the stock sits closer to its long-term average again, and that changes the risk/reward, especially considering the abruptness of this re-rating. I simply don’t think this is the moment where ASML doubles from here anytime soon, nor do I think it’s going to collapse. Most likely the stock goes sideways for a bit and that’s fine. But with this kind of volatility in the market, going sideways isn’t a luxury, but opportunity cost.
And that’s exactly where my decision came from. Not fear, not profit protection, not lack of conviction, just pure portfolio math. I don’t mind holding a stock that fluctuates. However, I don’t see much point in holding a stock at the 1–2-year price target I had envisioned when I bought it. The market hands out better alternatives almost daily.
That’s why I rotated the 10k from the sell straight into Visa. A company that is no worse than ASML in terms of dominance, moat, or predictability, just in an entirely different sector. Visa trades at a forward P/E of around 25, the same level it reached during the 2022 lows. Net income and free cash flow are growing in the mid-teens as always, revenue around 11%, and FCF margins are an absurd 56%. So why am I even talking about it? Everyone knows that Visa is an incredible business with a balance sheet straight from Buffett’s dreams. Visa prints cash, Visa grows, Visa compounds. There isn’t much more to add.
Again, ASML is a great company with potential for the future, but short-term I don’t see much more wiggle room. I just think Visa’s current setup offers a better balance of growth, valuation, and risk, and that’s what counts in my opinion. ASML remains a world-class compounder, and I’ll almost certainly own it again.
AI portfolio
I realized that my portfolio is very tech-heavy and has been underperforming the market the last few days. I thought I would ask several AIs (for fun) how they would adjust my portfolio to remain growth-oriented but with more diversification and some stability.
Here is the list:
Tech:
6% $NV
5% $2330
5% $PANW (+0,77%) (new)
6% $INTU (-0,59%) (new)
Industry:
3% $ETN (+0,21%) (new)
Health:
4% $LLY (-0,46%) (new)
3% $ISRG (-0,19%) (new)
Finances:
4% $V (+0,03%)
3% $NU (+0,49%)
Energy/commodities:
6% $LIN (-0,6%) (new)
2% $NEE (-0,05%) (new)
Infrastructure:
3% $WM (+0%) (new)
Consumption:
9% $COST (+0,23%) (new)
The Ki:
BYD, Xiaomi, Iris Energy, Hims and Hers, Sofi, Applied Digital, Coreweave, Ondas, Rocket lab. Quasi China and all the hype stocks
However, AI has been arguing with itself. It thought Crowdstrike should be replaced by Palo Alto and, if Palo Alto was in, it should be replaced by Crowdstrike. The same with Novo and Eli lilly, visa and mastercard, salesforce and service now.
What do you think of the AI "optimized portfolio"?

Too cheap to ignore
Took some money out of $ASML (+0,47%) and bought more $HIMS (+0,85%) . The market just doesn’t understand….
The path to financial freedom
My path to financial freedom. My investment horizon is around 15 years.
- Monthly savings rate 2600 Euro
- 1000 Euro ETF savings plan
- 1150 Euro individual shares
- 400 Euro BTC savings plan + 20000 Euro cash still invested to reach 20 % of the portfolio
- 50 Euro P2P Go&Grow
Target weighting
30 % ETF $SP20 (-0,49%)
30 % shares
$AMD (-1,35%)
$ASML (+0,47%)
$SHOP (-0,1%)
$NOW (-0,24%)
$NU (+0,49%)
$META (+0,49%)
$FTNT (+1,06%)
$ANET (-1,29%)
$NFLX (-2,31%)
$APP (+0,61%)
$CRWD (-2,31%)
20% Bitcoin $BTC (+0,93%)
10% gold $EWG2 (-0,15%)
5% P2P Bondora Go&Grow
5% Cash cushion $ERNX (-0,03%)
the strategy is always individually adapted.
30% GTAA
30% 3xGTAA
30% 2xSpytips
10% cash
= approx. 2,3%pM
= 7080€pM gross
= 5200€pM net
= Financial freedom today.
But I'll probably always be the Don Quixote of investment strategies. 🤷
Tips for your next purchase
Hello everyone, now that I am 18, I have opened my own brokerage account. Before that I had all my investments through my mother. There I had the $VWRL (-0,25%)
$NOVO B (+0,04%)
$NVDA (+1,59%) ,$ASML (+0,47%) , $Sales
$ADBE (-0,39%) , $ANET (-1,29%) . Due to the share transfer fee, I decided to take advantage of the €1 selling fee and sell everything there. In total, I made a profit of around €200. I have already made a few purchases in my portfolio, but now I have around €4000-4500 free to invest due to the sales, which could also be a good time to make better purchases than at that time. I would therefore like to get some suggestions from you. I would like to have one ETF in my portfolio, which I will save around €250 per month. The rest is open, please give me specific suggestions as to which stocks you consider to be top buys at the moment and also with a specific investment amount of my available money. Please find attached my portfolio and the positions I already have.
Portfolio November 2025
Dear fellow campaigners,
I have restructured my portfolio far too often for the short time I have had it, and I was actually satisfied with this portfolio.
But now I think that I have given the "tech hype" too much space in my portfolio.
As I have most of the positions in the $VWRL (-0,25%) but I had the feeling that I was missing out on returns, I would be interested in your opinion, would you sell your shares in $NVDA (+1,59%)
$ASML (+0,47%)
$GOOGL (-0,35%) and $MSFT (-0,56%) reduce or perhaps even liquidate them?
I would still like to focus on growth, I would be interested in your top growth stocks, perhaps not in the tech sector or rather in another tech direction, e.g. automation technology.
LG Flo
🎯 Top opportunities this week - week 46. Our hot picks.
This week we have three exciting setups on the radar 👇
***
📈 $AMD (-1,35%) (Advanced Micro Devices)
Technical support meets seasonal strength - the zone remains exciting for long setups.
***
💸 $DLTR (+0,73%) (Dollar Tree Inc.)
After a prolonged recovery, the price could break out again towards new local highs.
***
🔵 $ASML (+0,47%) (ASML Holding NV)
The upward trend remains intact - we are watching the blue zone for possible entries.
Basic knowledge: Price targets, consensus and conflicts - the anatomy of analyst opinions
Reading time: approx. 9 minutes
Analysts enjoy a special status on the markets. Their price targets move shares, their assessments make the headlines and their models are used in fund decisions. However, those who use their forecasts without critically examining them often overlook the fact that analyst reports are not objective market barometers - but products with their own interests, assumptions and systematic distortions.
Empirical evidence shows: Analysts are surprisingly often wrong. A 20-year meta-study by the University of Iowa found that, on average, only around 47% of share price targets are achieved within twelve months. Even more clearly, the hit rate for the most optimistic forecasts was less than 30% in some cases. The much-cited EPS forecast is not infallible either - according to Refinitiv data, consensus estimates at the end of the year deviate on average by 8-12% from the actual result.
The problem lies less in the methodology than in the system. The majority of analysts work at investment banks, which also support issues or maintain business relationships with the analyzed companies. Negative ratings are rare there. According to FactSet, of over 14,000 recommendations in the S&P 500 universe, over 55% were recently "buy" and only 6% "sell" - an imbalance that can hardly be explained by optimism alone.
Example 1: $AMZN (-0,05%) (Amazon)
Before the dotcom bubble, the average price target for Amazon in March 2000 was around USD 100 - a few weeks later, the share price fell by 90 %. Even in 2014, when margins were shrinking and analysts were basing their models on short-term profits, 80% of the ratings were "hold" or "sell". Those who invested against the consensus back then multiplied their capital by 2020.
The pattern: analysts extrapolate the present into the future. In boom phases they overestimate growth, in crises they underestimate recovery.
Example 2: $TSLA (+1,09%) (Tesla)
In 2020, Goldman Sachs rated Tesla with a price target of USD 780 - when the share was at 400. Six months later, it had tripled. In 2022, many firms lowered their targets to below USD 200 after the share price had already fallen sharply. So the adjustment came after the movement. Analysts react, they rarely anticipate.
Example 3: $SPOT (-1,62%) (Spotify)
In 2022, major banks such as Morgan Stanley issued share price targets of USD 100 - on the grounds that the streaming model would remain permanently loss-making. Shortly afterwards, Spotify actually improved its gross margin and became operationally profitable. The share price doubled within a year. The estimates were correct, only the time horizon was wrong: analysts usually model twelve months, investors think five years.
Why this is the case
Analysts are caught between two worlds:
Sales and customer loyalty - their primary job is to provide institutional investors with information, not private investors. Their reports are part of a service designed to generate trust - not necessarily returns.
Reputation protection - If you deviate too much, you risk performing poorly in the rankings of the major data services (Institutional Investor). This is why many forecasts are within a narrow consensus band.
This leads to a herd instinct: the more analysts call a stock a "buy", the less anyone wants to deviate. Conversely, reputational pressure has a dampening effect in times of crisis - nobody wants to become bullish again too soon. As a result, analysts are often right in their diagnosis but wrong in their timing.
The most important companies and voices
A few companies dominate the global analyst landscape. In the English-speaking world, these include
- Goldman Sachs, Morgan Stanley, J.P. Morgan, Bank of America - with a strong weighting in institutional research.
- UBS, Barclays, Deutsche Bank, Credit Suisse (now integrated into UBS) - often with very sector-specific analyst teams.
- Morningstar - independent, with a focus on fundamental valuation (fair value models, "economic moat" approach).
- CFRA Research, Argus, Jefferies, Wedbush - smaller, but often more contrarian firms with a higher hit rate for second-line stocks.
- Bernstein Research is regarded as particularly analytical and quantitative - often with clear deviations from the mainstream.
Platforms such as TipRanks or Refinitiv StarMine, which track the performance of individual analysts over the years and make it assessable, offer an interesting addition. This shows, for example: The top 10% of analysts slightly outperform the market - the remaining 90% do not.
Which key figures really count
The classic recommendation ("buy", "hold", "sell") is striking, but superficial. The quantitative key figures in the background of the models are more meaningful. Some of them deserve more attention than the headlines:
EPS revision rate - measures how much earnings estimates are adjusted over time. Positive revisions correlate with share price increases.
Target price gap - the difference between the current share price and the average target price. A gap of over 20 % looks attractive, but is only relevant if the estimates remain stable.
Dispersion of estimates - wide spread between analysts indicates uncertainty; narrow range signals consensus (and therefore less potential for surprises).
Valuation spread - ratio between highest and lowest price target. Wide spreads are often found with disruptive companies (e.g. $TSLA (+1,09%) , $PLTR (+2,12%) ).
Earnings surprise rate - measures how often a company beats analysts' estimates. Companies with repeated "beats" (e.g. $V (+0,03%) , $ASML (+0,47%) ) enjoy a structural valuation premium.
These metrics are not a substitute, but a realistic corrective. While ratings contain emotion, ratios provide evidence.
Let's take $INOD (+1,47%) (Innodata). In 2022, the average price target was still USD 3, hardly anyone saw potential. When the AI hype began, the same companies revised their models - now the fair value was USD 9. The share price jumped to USD 13, not because the business tripled overnight, but because the analysts subsequently adjusted their assumptions.
Similarly with $NU (+0,49%) (Nu Holdings): Long labeled as an overpriced fintech, the tone changed as soon as profitability became apparent.
These examples show: Analysts are heavily calibrated with hindsight. The real opportunities lie where there is still no coverage or where the narrative changes.
Analysts provide valuable data points, but no direction. Their reports can help lay a foundation - but they are no substitute for your own assessment. It is crucial to understand how their models are created and what assumptions or conflicts of interest are at work in them.
Empirically, it can be stated: Analysts offer solid fundamental data on average, but weaken in terms of forecast quality and timing. The best strategy is therefore to use their analyses as input - but to consistently make your own judgment.
In other words: analysts draw the map, but each investor must determine the path for themselves.
How do you use analyst estimates? As a guide, as a counter-indicator or not at all?
Some good news out of ASML today
$ASML (+0,47%) saying they're committed to working with China. Still no companies close to being where ASML is today. It has dipped this week but fully expect it to rise next week.
Títulos em alta
Principais criadores desta semana
